OptiNose, Inc. OPTN
9.60 0.00 (+0.00%)
At closeMay 21, 2025, 4:00 PM EDT
9.60 Day range 9.60
52-week range unavailable
- YTD
- +43.71%
- 1 year
- -46.67%
News
gurufocus.com Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia PR Newswire
gurufocus.com Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
gurufocus.com Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
seekingalpha.com U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
zacks.com OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates OptiNose (OPTN) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.80 per share a year ago.
businesswire.com OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
zacks.com OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates OptiNose (OPTN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.35 per share a year ago.
zacks.com Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 143.1% in OptiNose (OPTN). While the effectiveness of this highly sought-after metric is questionable, the…
businesswire.com OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
zacks.com OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
globenewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders NEW YORK, March 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
prnewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN NEW YORK , March 20, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
https://thefly.com Optinose just downgraded at Piper Sandler, here's why 20 Mar
globenewswire.com OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals MONSEY, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of OptiNose, Inc. (Nasdaq: OPTN) (“OptiNose”) to Paratek…
businesswire.com Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Optinose (NASDAQ:OPTN) for possible breaches of fiduciary duty and other violations of law in its transaction with Paratek. Click here to…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com US Stocks Likely To Open Lower After Fed Decision: Any Pullback In Equities 'Offers An Opportunity,' Says Expert U.S. stock futures rose on Thursday following the Federal Open Market Committee's decision on Wednesday calling inflation 'transitory'.
globenewswire.com Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced…
globenewswire.com Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 ‑ million ‑ patient market Acquisition advances Paratek's…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
globenewswire.com Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% Preliminary XHANCE prescription growth rate from third quarter to fourth…
globenewswire.com Optinose Announces 1-for-15 Reverse Stock Split YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today…
globenewswire.com Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced…
benzinga.com Earnings Scheduled For November 12, 2024 - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Earnings Scheduled For March 7, 2024 Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.- benzinga.com Earnings Scheduled For November 9, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 65 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 69 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 212 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 85 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 63 companies hit new 52-week lows.
- benzinga.com Earnings Scheduled For May 11, 2023 Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its…
- benzinga.com Earnings Scheduled For March 7, 2023 Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for its fourth quarter. • Xtant Medical Holdings (AMEX:XTNT) is expected to report earnings for its fourth…
- benzinga.com Earnings Scheduled For August 11, 2022 Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
benzinga.com Earnings Scheduled For May 12, 2022 Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.- benzinga.com Earnings Scheduled For March 8, 2022 Companies Reporting Before The Bell • Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million.
- benzinga.com 80 Biggest Movers From Yesterday Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
- benzinga.com 53 Stocks Moving In Tuesday's Mid-Day Session Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss.
- benzinga.com Earnings Scheduled For November 15, 2021 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For August 11, 2021 Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Before 10 a.m. ET Thursday, 42 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.